Gaucher Disease – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Gaucher Disease Emerging Therapy and TPP Insights

Thelansis’s “Gaucher Disease Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Gaucher Disease Overview

Gaucher disease is the most common lysosomal storage disorder, caused by autosomal recessive mutations in the GBA1 gene encoding glucocerebrosidase. This deficiency drives the progressive intralysosomal accumulation of glucosylceramide within reticuloendothelial macrophages, forming lipid-laden “Gaucher cells.” The disease spans three subtypes: Type 1 (non-neuronopathic and most prevalent), Type 2 (acutely fatal infantile neuronopathic), and Type 3 (chronic neuronopathic). Systemic features include hepatosplenomegaly, anemia, thrombocytopenia, and skeletal damage like avascular necrosis, while oculomotor apraxia and ataxia track with neuronopathic forms. Diagnosis utilizes dried blood spot enzyme assays, GBA1 genotyping, and sensitive plasma biomarkers like glucosylsphingosine (lyso-Gb1). Traditional enzyme replacement therapies (imiglucerase, velaglucerase alfa, taliglucerase alfa) and oral substrate reduction therapies (eliglustat, miglustat) effectively reverse visceral and bone disease but fail to cross the blood-brain barrier. However, the therapeutic landscape has reached a historic inflection point: the FDA granted Priority Review to Sanofi’s brain-penetrant oral glucosylceramide synthase inhibitor venglustat, setting a regulatory decision date for November 25, 2026. Backed by Phase 3 LEAP2MONO success, venglustat stands to become the first approved modifier of neurological decline in Type 3 disease, radically shifting long-term prognosis.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)